Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

L. Garland; L. A. Robinson; H. Wagner

Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

L. Garland, L. A. Robinson, H. Wagner

Research output: Contribution to journal › Review article › peer-review

Abstract

Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

Original language	English (US)
Pages (from-to)	69-100
Number of pages	32
Journal	Chest Surgery Clinics of North America
Volume	11
Issue number	1
State	Published - 2001

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{04d4b5bb74dd49cf86efd33043ce4300,

title = "Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer",

abstract = "Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.",

author = "L. Garland and Robinson, {L. A.} and H. Wagner",

year = "2001",

language = "English (US)",

volume = "11",

pages = "69--100",

journal = "Chest Surgery Clinics of North America",

issn = "1052-3359",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

AU - Garland, L.

AU - Robinson, L. A.

AU - Wagner, H.

PY - 2001

Y1 - 2001

N2 - Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

AB - Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0035103952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035103952&partnerID=8YFLogxK

M3 - Review article

C2 - 11253602

AN - SCOPUS:0035103952

SN - 1052-3359

VL - 11

SP - 69

EP - 100

JO - Chest Surgery Clinics of North America

JF - Chest Surgery Clinics of North America

IS - 1

ER -

Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this